Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Oncotargets and Therapy|June 20, 2015
Extracellular matrix as target for antitumor therapyRevekka Harisi, Andras JeneyCancer Biology & Therapy|August 19, 2007
Extracellular matrix induces doxorubicin-resistance in human osteosarcoma cells by suppression of p53 functionRevekka Harisi, Jozsef Dudas, Julia Nagy-Olah, et al.Anticancer Research|August 8, 2009
Differential inhibition of single and cluster type tumor cell migrationRevekka Harisi, Istvan Kenessey, Julia N Olah, et al.Anticancer Research|September 26, 2025
Differential PCNA Expression Between Neoplastic and Adjacent Mucosa as a Prognostic Marker in Colorectal Adenoma-Carcinoma ProgressionRevekka Harisi, Balazs Jaray, Attila Zsirka, et al.Cancer Chemotherapy and Pharmacology|March 15, 2006
Repopulation of osteosarcoma cells after treatment with doxorubicin in the presence of extracellular matrix biopolymersRevekka Harisi, József Dudás, Gábor Pogány, et al.Cell Biology International|October 26, 2005
Invasive growth and topoisomerase-switch induced by tumorous extracellular matrix in osteosarcoma cell cultureRevekka Harisi, József Dudás, Ferenc Timár, et al.Hepato-Gastroenterology|May 30, 2008
Evaluation and comparison of the clinical, surgical and pathological TNM staging of colorectal cancerRevekka Harisi, Zsuzsanna Schaff, Lajos Flautner, et al.Anticancer Research|May 5, 2005
Antiproliferative and antimigratory effects of doxorubicin in human osteosarcoma cells exposed to extracellular matrixRevekka Harisi, József Dudás, Ferenc Tímár, et al.Anticancer Research|December 13, 2005
Inhibition of EGFR tyrosine-kinase in NSCLC treatment: the Hungarian experience with gefitinib in the context of an expanded access programmeGyula Ostoros, Revekka Harisi, Gabor Kovacs, et al.Anticancer Research|August 6, 2005
Molecular prognostic markers in recurrent and in non-recurrent epithelial ovarian cancerAttila Demeter, Istvan Sziller, Zsolt Csapo, et al.Pageof 2